Companies around the world are lining up for pole position in the race to develop gene editing technology that could change the world of biotech. “Patent filings related to gene editing have increased 60-fold over the past 10 years,” said Mike Ward, global head of thought leadership in life sciences and healthcare at Clarivate, in an email. “This exponential growth reflects the intense innovation and commercial interest in gene editing technologies. It also suggests we may see an acceleration in the development of new gene editing tools and therapies in the coming years.” As global superpowers like the U.S. and China vie for biotech supremacy, a recent report from Clarivate, an intelligence solutions company, took a closer look at the companies driving innovation in the burgeoning space. The analysts flagged several players uniquely poised to leap ahead of the competition, not only with flexible and innovative platforms, but the proprietary rights to potentially game-changing technology. Others could solve problems that have plagued other genetic engineering technologies, such as serious safety issues triggered by editing mistakes, Ward said.

Full report : 4 innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.